LivaNova PLC is a global medical technology and innovation company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 4,000 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide.
20 Eastbourne Terrace, London W2 6LG
Phone: 442033250662
www.livanova.com
No summary available.
https://www.investing.com/news/company-news/livanova-shares-target-lifted-to-75-after-surpassing-2q-expectations-93CH-3546703
No summary available.
LivaNova (NASDAQ: LIVN ) just reported results for the second quarter of 2024. LivaNova reported earnings per share of 93 cents. This was above the analyst estimate for EPS of 78 cents. The company reported revenue of $318.60 million. This was 4.73% better than the analyst estimate for revenue of $304.21 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at [email protected]. More From InvestorPlace Legendary Investor Predicts: “Forget AI… THIS Technology Is the Future” The post LIVN Stock Earnings: LivaNova Beats EPS, Beats Revenue for Q2 2024 appeared first on InvestorPlace .
No summary available.
https://www.investing.com/news/company-news/stifel-lifts-livanova-stock-pt-to-72-maintains-buy-rating-ahead-of-2q24-earnings-93CH-3536999
NEW YORK, June 22, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC (“LivaNova” or the “Company”) (NASDAQ: LIVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
